Tuis500087 • BOM
add
Cipla Ltd
Vorige sluiting
₹1 508,55
Dagwisseling
₹1 500,35 - ₹1 520,00
Jaarwisseling
₹1 310,05 - ₹1 702,00
Markkapitalisasie
1,22Â bn INR
Gemiddelde volume
30,28Â k
P/V-verhouding
23,22
Dividend-opbrengs
0,86%
PrimĂŞre beurs
NSE
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(INR) | Mrt. 2025info | J/J-verandering |
---|---|---|
Inkomste | 67,20Â mjd | 8,87% |
Bedryfskoste | 29,47Â mjd | 6,75% |
Netto inkomste | 12,22Â mjd | 30,12% |
Netto winsgrens | 18,18 | 19,53% |
Wins per aandeel | 15,12 | 30,12% |
EBITDA | 15,60Â mjd | 15,81% |
Effektiewe belastingkoers | 18,70% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(INR) | Mrt. 2025info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 106,18Â mjd | 36,20% |
Totale bates | 373,87Â mjd | 14,27% |
Totale aanspreeklikheid | 60,98Â mjd | 3,09% |
Totale ekwiteit | 312,89 mjd | — |
Uitstaande aandele | 807,62 m | — |
Prys om te bespreek | 3,91 | — |
Opbrengs op bates | — | — |
Opbrengs op kapitaal | 11,02% | — |
Kontantvloei
Netto kontantverandering
(INR) | Mrt. 2025info | J/J-verandering |
---|---|---|
Netto inkomste | 12,22Â mjd | 30,12% |
Kontant van bedrywe | — | — |
Kontant van beleggings | — | — |
Kontant van finansiering | — | — |
Netto kontantverandering | — | — |
Beskikbare kontantvloei | — | — |
Meer oor
Cipla Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, paediatric and various other medical conditions. Cipla has 47 manufacturing locations across the world and sells its products in 86 countries. It is the third-largest drug producer in India. Wikipedia
HUB
Gestig
1935
Hoofkwartier
Webwerf
Werknemers
30Â 313